{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:36:06Z","timestamp":1772249766529,"version":"3.50.1"},"reference-count":36,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/100007397","name":"Univerzita Karlova","doi-asserted-by":"publisher","award":["Project SVV 260185"],"award-info":[{"award-number":["Project SVV 260185"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2015.00304","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T01:58:53Z","timestamp":1451959133000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Entecavir Interacts with Influx Transporters hOAT1, hCNT2, hCNT3, but Not with hOCT2: The Potential for Renal Transporter-Mediated Cytotoxicity and Drug\u2013Drug Interactions"],"prefix":"10.3389","volume":"6","author":[{"given":"Jana","family":"Mand\u00edkov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Volkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"P\u00e1vek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Navr\u00e1tilov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Hyr\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zlatko","family":"Janeba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Pavl\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"B\u00e1rta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franti\u0161ek","family":"Trejtnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2016,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1177\/0091270007304780","article-title":"Absence of a pharmacokinetic interaction between entecavir and adefovir.","volume":"47","author":"Bifano","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10254-002-0003-8","article-title":"Transport of organic anions across the basolateral membrane of proximal tubule cells.","volume":"146","author":"Burckhardt","year":"2003","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/med.20221","article-title":"Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition.","volume":"32","author":"Cano-Soldado","year":"2012","journal-title":"Med. Res. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3350\/kjhep.2012.18.1.75","article-title":"High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B.","volume":"18","author":"Chae","year":"2012","journal-title":"Korean J. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1128\/AAC.01183-08","article-title":"Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.","volume":"53","author":"Cihlar","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1124\/mol.56.3.570","article-title":"The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.","volume":"56","author":"Cihlar","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2165\/00003088-199936020-00004","article-title":"Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.","volume":"36","author":"Cundy","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jchromb.2005.10.015","article-title":"Sensitive assay for determining plasma tenofovir concentrations by LC\/MS\/MS.","volume":"830","author":"Delahunty","year":"2006","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ejphar.2008.02.085","article-title":"Mechanisms of renal anionic drug transport.","volume":"585","author":"El-Sheikh","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/mol.110.063552","article-title":"The human concentrative nucleoside transporter-3 C602R variant shows impaired sorting to lipid rafts and altered specificity for nucleoside-derived drugs.","volume":"78","author":"Errasti-Murugarren","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00424-003-1107-y","article-title":"The concentrative nucleoside transporter family, SLC28.","volume":"447","author":"Gray","year":"2004","journal-title":"Pflugers. Arch."},{"key":"B12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1681\/ASN.V113383","article-title":"Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1.","volume":"11","author":"Ho","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/01.aids.0000162333.35686.4c","article-title":"Renal tubular transporters and antiviral drugs: an update.","volume":"19","author":"Izzedine","year":"2005","journal-title":"AIDS"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1016\/j.transproceed.2010.05.127","article-title":"Efficacy and safety of entecavir and\/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant.","volume":"42","author":"Jim\u00e9nez-P\u00e9rez","year":"2010","journal-title":"Transplant. Proc."},{"key":"B15","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/0091270005278949","article-title":"Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration.","volume":"4","author":"Kearney","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"B16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/mol.105.015768","article-title":"A comparison of the transportability, and its role in cytotoxicity of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems.","volume":"69","author":"King","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.109.002014","article-title":"Xenobiotics, bile acid, and cholesterol transporters: function and regulation.","volume":"62","author":"Klaassen","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s00424-003-1089-9","article-title":"The SLC22 drug transporter family.","volume":"447","author":"Koepsell","year":"2004","journal-title":"Pflugers. Arch."},{"key":"B19","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1124\/mol.60.5.1143","article-title":"Acquisition of human concentrative nucleoside transporter 2 (hcnt2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells.","volume":"60","author":"Lang","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/hep.24361","article-title":"Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.tox.2013.07.004","article-title":"Interactions with selected drug renal transporters and transporter-mediated cytotoxicity in antiviral agents from the group of acyclic nucleoside phosphonates.","volume":"311","author":"Mandikova","year":"2013","journal-title":"Toxicology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ejphar.2003.08.076","article-title":"Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney.","volume":"479","author":"Mangravite","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.clinthera.2006.02.012","article-title":"Entecavir for the treatment of chronic hepatitis B virus infection.","volume":"28","author":"Matthews","year":"2006","journal-title":"Clin. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.pharmthera.2011.06.007","article-title":"Drug uptake transporters in antiretroviral therapy.","volume":"132","author":"Minuesa","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/15257771003729823","article-title":"Role of nucleoside transporters in nucleoside-derived drug sensitivity.","volume":"29","author":"Molina-Arcas","year":"2010","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"B26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2133\/dmpk.20.452","article-title":"Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies.","volume":"20","author":"Nishimura","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.4065\/mcp.2011.0309","article-title":"Antiviral drugs for viruses other than human immunodeficiency virus.","volume":"86","author":"Razonable","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1074\/jbc.M007746200","article-title":"Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib).","volume":"276","author":"Ritzel","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1523-1755.2005.00444.x","article-title":"Expression of concentrative nucleoside transporters SLC28 (CNT1, CNT2, and CNT3) along the rat nephron: effect of diabetes.","volume":"68","author":"Rodr\u00edguez-Mulero","year":"2005","journal-title":"Kidney Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2165\/00003495-200969080-00005","article-title":"Entecavir: a review of its use in chronic hepatitis B.","volume":"69","author":"Scott","year":"2009","journal-title":"Drugs"},{"issue":"393","key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-393","article-title":"Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.","volume":"8","author":"Sheng","year":"2011","journal-title":"Virol. J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s11095-006-9196-x","article-title":"Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).","volume":"24","author":"Uwai","year":"2007","journal-title":"Pharm. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ejps.2012.12.024","article-title":"OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485.","volume":"48","author":"Xu","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2006.10.062","article-title":"Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters.","volume":"557","author":"Yamamoto","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1177\/0091270006293304","article-title":"Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects.","volume":"46","author":"Yan","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lfs.2011.03.018","article-title":"Organic anion and cation transporters are possibly involved in renal excretion of entecavir in rats.","volume":"89","author":"Yanxiao","year":"2011","journal-title":"Life Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T18:09:36Z","timestamp":1654020576000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fphar.2015.00304\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,5]]},"references-count":36,"URL":"https:\/\/doi.org\/10.3389\/fphar.2015.00304","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726089460.793520299","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,5]]}}}